Diabetes and Metabolism Seminar Series

University of Washington



Targeted Mass Spectrometry Assays for Diabetes and Obesity Research (TaMADOR)

May 6, 2024, 8:30AM-3:30PM

UW Medicine at South Lake Union, Brotman Auditorium (D Bldg), 850 Republican St. Seattle 98109

Register here: https://diabetesmetabseminars.com/

8:00-8:30am	Breakfast in lobby
8:30-8:45am	Salvatore Sechi, Ph.D., NIDDK/NIH History and purpose of TaMADOR
8:45-9:20am	Des Schatz, M.D. , University of Florida Clinical Trials and Biomarkers
9:20-9:55am	Cate Speake, Ph.D., Benaroya Research Institute Biomarkers in Type 1 Diabetes Research
9:55-10:20am	Jenny Van Eyk, Ph.D., Cedars-Sinai (Virtual) Assessment of obesity and diabetes as co-morbidities in precision health
10:20-10:30am	Coffee Break in lobby
10:30-10:55am	Andy Hoofnagle, MD PhD, University of Washington The TaMADOR Consortium: Interlaboratory transfer of a combined antibody-free insulin/C-peptide assay
10:55-11:20am	Jessica Becker, MLS(ASCP), MS , University of Washington Preparing for the interlaboratory transfer of a novel assay to measure glucagon and oxyntomodulin
11:20-11:45pm	Weijun Qian, Ph.D., PNNL LC-MS assays for specific prohormone proteoforms (insulin and IAPP) relevant to type 1 diabetes
11:45-12:10pm	Sara Shijo, University of Washington Progress toward a proteolysis-peptide immunoaffinity enrichment-LC-MS/MS assay for proinsulin
12:10-1:00pm	Lunch in lobby
1:00-1:35pm	David Sacks, MB ChB, NIH Clinical Center Hemoglobin A1c as a Clinical Biomarker
1:35-2:10pm	Irl Hirsch, M.D., University of Washington Past, Present, and Future of T1D Biomarkers
2:10-2:35pm	Tai-Du Lin, Ph.D., PNNL LC-MS assays for obesity biomarkers
2:35-3:00pm	Michael MacCoss, Ph.D., University of Washington Using Mass Spectrometry for Monitoring Patient Response to Therapy



3:00-3:30pm



Top-down proteomics for elucidating cellular prohormone proteoforms and novel analytical

Weijun Qian, Ph.D., PNNL and Jun Qu, Ph.D., University of Buffalo

approaches for enhancing sensitivity

